1. Medtech Insight

Micell's Optimism In MiStent Biosorbable Polymer Stent Grows With Retrospective Study

A retrospective propensity-matched comparison of Micell’s MiStent sirolimus-eluting absorbable polymer coronary stent system to Abbott’s popular Xience V everolimus-eluting stent suggests that MiStent has a good chance of outperforming Xience in the DESSOLVE III randomized trial.

A retrospective propensity-matched comparison of Micell Technologies Inc.'s Micell’s MiStent sirolimus-eluting absorbable polymer coronary stent system to Abbott Vascular's popular Xience V everolimus-eluting stent suggests that MiStent has a good chance of outperforming Xience in the DESSOLVE III randomized trial.

MiStent elutes sirolimus, a common anti-inflammatory drug, from polylactic-co-glycolic acid (PLGA), a common biodegradable polymer coating, but whereas most drug-eluting stent coatings are made by dissolving the drug and the polymer in an organic solvent, Micell has a proprietary supercritical fluid technology to create a solvent-free, dry powder coating that can be applied to the stent as a smooth film with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight